期刊文献+

应用ROC曲线评价尿蛋白定量与定性检测对蛋白尿的诊断价值 被引量:4

下载PDF
导出
摘要 目的观察尿蛋白定量与定性检测方法间的差异,确定诊断蛋白尿的临界值,评价尿蛋白定量和定性检测方法对蛋白尿的诊断价值。方法尿蛋白阴性组146例和尿蛋白阳性组79例,两组分别进行尿蛋白(UP)定量、尿肌酐(UCr)和磺基水杨酸法、尿干化学试纸条法尿蛋白定性的检测,并绘制ROC曲线进行分析。结果 UP和UP/UCr的ROC曲线下面积(AUC)分别为0.992、0.935,两者间AUC差异有统计学意义(P<0.05)。UP和UP/UCr判定尿蛋白阳性的临界值分别为148 mg/L和8.34mg/mmol,诊断灵敏度分别为96.2%和83.5%,特异度分别为95.9%和94.5%,Kappa值分别为0.928 7和0.792 0。与磺基水杨酸法进行比较,干化学试纸条法检测尿蛋白的灵敏度为86.1%,特异度为97.9%,Kappa值为0.860 3,差异无统计学意义(P>0.05)。以148 mg/L为临界值,UP定量分析法诊断蛋白尿的准确度高于干化学试纸条法。结论应用ROC曲线法确定尿蛋白定量检测方法的临界值,有助于提高蛋白尿的筛查的准确性。
出处 《国际检验医学杂志》 CAS 2011年第9期986-987,共2页 International Journal of Laboratory Medicine
  • 相关文献

参考文献7

二级参考文献28

  • 1辛岗,王芳,王梅,焦莉莉,徐国宾,王海燕.点时间尿蛋白与尿肌酐比值检测的临床应用评价[J].中华肾脏病杂志,2005,21(5):247-250. 被引量:45
  • 2张路霞,王梅,王海燕.慢性肾脏病的流行病学研究[J].中华肾脏病杂志,2005,21(7):425-428. 被引量:69
  • 3Xue JL,Ma JZ,Louis TA,et al.Forecast of the number of patients with end-stage renal disease in the United States to the year 2010.J Am Soc Nephrol,2001,12:2753-2758.
  • 4Coresh J,Astor BC,Green T,et al.Prevalence of Chronic Kidney Disease and Decreased Kidney Function in the Adult US Population:Third National Health and Nutrition Examination Survey.Am J Kidney Dis,2003,41:1-12.
  • 5Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on prevention,detection,evaluation and treatment of high blood pressure.JAMA,2003,21:2560-2572.
  • 6Anonymous.KDOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Kidney Disease Outcome Quality Initiative.Am J Kidney Dis,2002,39 Suppl 2:S1-S246.
  • 7Chadban SJ,Briganti EM,Kerr PG,et al.Prevalence of kidney damage in Australian adults:the AusDiab kidney study.J Am Soc Nephrol,2003,14:S131-S138.
  • 8Garg AX,Kiberd BA,Clark WF,et al.Albuminuria and renal insufficiency prevalence guides population screening:results form the NHANESⅢ.Kidney Int,2002,61:2165-2175.
  • 9Ramirez SP,Mcclellan W,Port FK,et al.Risk factors for proteinuria in a large,multiracial,southeast Asian population.J Am Soc Nephrol,2002,13:1907-1917.
  • 10Levey AS,Eckardt KU,Tsukamoto Y,et al.Definition and classification of chronic kidney disease:a position statement from Kidney Disease:Improving Global Outcomes (KDIGO).Kidney Int,2005,67:2089-2100.

共引文献397

同被引文献40

  • 1刘薇,尹平河,赵玲.荧光法测定十二烷基苯磺酸钠鉴别潲水油的研究[J].中国油脂,2005,30(5):24-26. 被引量:102
  • 2陈卫中,潘晓平,宋兴勃,倪宗瓒.ROC曲线中最佳工作点的选择[J].中国卫生统计,2006,23(2):157-158. 被引量:95
  • 3Mohaupt M.Molecular aspects of preeclampsia[J].Mol Aspects Med,2007,28(12):169-191.
  • 4Robert W,Arun J,Rebecca G,et al.Soluble fms-like tyrosine ki-nase1(sFlt1),Endoglin and Placental Growth Factor(PIGF)in preeclampsia among high risk pregnancies[J].Plos One,2010,5(10):32-63.
  • 5Victoria L,Bill S,Julia V,et al.Failure to up-regulate VEGF165b in maternal plasma is a rsttrimester predictive marker for pre-eclamp-sia[J].Clinical Science,2009,116(38):265-272.
  • 6Bridges JP,Gilbert JS,Colson D,et al.Oxidative stress contrib-utes to soluble fms-like tyrosine kinase-1induced vascular dys-function in pregnant rats[J].Am J Hypertens,2009,22(19):564-568.
  • 7Gu Y,Lewis DF,Wang Y,et al.Placental productions and expres-sions of soluble endoglin,soluble fms-like tyrosine kinase recep-tor-1and placental growth factor in normal and preeclamptic preg-nancies[J].J Clin Endocrinol Metab,2008,93(21):260-266.
  • 8Noori M,Donald AE,Angelakopoulou A,et al.Prospective study of placental angiogenic factors and maternal vascular function be-fore and after preeclampsia and gestational hypertension[J].Cir-culation,2010,122(5):478-487.
  • 9Chafetz I,Kuhnreich I,Sammar M,et al.First-trimester placental protein13screening for preeclampsia and intrauterine growth re-striction[J].Am J Obstet Gynecol,2007,197(1):35-37.
  • 10Romem R,Kusanovic JP,Than NG,et al.First-trimester maternal serum PP-13in the risk assessment for preeclampsia[J].Am J Obstet Gynecol,2008,199(2):122-124.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部